Market Size of Hepatitis Therapeutics Industry
| Study Period | 2021 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 3.50 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Hepatitis Therapeutics Market Analysis
During the time frame of the forecast, the hepatitis therapeutics market is expected to grow at a CAGR of 3.5%.
The impact of COVID-19 on healthcare services had a substantial impact on the delivery of care and outcomes for patients with chronic diseases. Therefore, there was a decline in the treatment, diagnosis, and follow-up of patients with hepatitis B and C, which had a significant impact on the healthcare industry. Additionally, clinical trials of the drugs were reduced as more and more companies delayed the start of most new courses in several countries. In addition, the COVID-19 epidemic saw a decline in outpatient services for patients with chronic hepatitis, which also had a significant impact on overall market growth. The study published in July 2021 in PubMed stated that the COVID-19 pandemic affected hepatitis prevention, testing, treatment, and vaccination services globally. But the return of elective care procedures around the world is likely to bring the market's growth back to where it was before the pandemic.
The market is anticipated to witness rapid growth due to the growing incidence of hepatitis, growing government support for awareness of hepatitis diseases, and increased availability of highly technologically advanced medical products. Hepatitis is an inflammation of the liver. Hepatitis may be due to drugs, alcohol consumption, or other medical conditions affecting the liver. But in most cases, it is caused by a virus called viral hepatitis, and the most common types are hepatitis A, B, and C. Hepatitis B is very common and can lead to severe cirrhosis of the liver, which can be fatal. Moreover, government initiatives to increase awareness regarding hepatitis and its treatment are anticipated to boost market growth over the forecast period. For instance, in June 2022, the "World Hepatitis Summit (WHS)" occurred as a virtual event. The World Hepatitis Summit 2022 was co-sponsored by the World Health Organization (WHO). The summit provides a platform for a broad hepatitis community to take stock of progress to date and share ideas, experiences, and best practises in addressing the many challenges of viral hepatitis.
Furthermore, according to the Hepatitis B Foundation 2022 update, two billion people have been infected with the hepatitis B virus (one out of three people). Approximately 1.5 million people become newly infected each year. Almost 300 million people are chronically infected. Thus, the increasing burden of hepatitis is propelling the growth of the market. Additionally, in March 2021, Dicerna Pharmaceuticals and Roche commenced the Phase II combination trial of the investigational GalXC RNAi candidate, RG6346, for the treatment of chronic hepatitis B virus (HBV) infection. In addition, in March 2022, VBI Vaccines Inc. received FDA approval for the 3-antigen HBV vaccine for adults in the United States, PreHevbrio for hepatitis B. Therefore, such research and development activities in the market are expected to drive market growth.
Therefore, the increase in the prevalence of the hepatitis B virus, the promising pipeline for hepatitis drugs, and government-sponsored programmes to encourage patients to accept hepatitis drugs are likely to drive the hepatitis therapeutics market over the forecast period. During the analysis period, the market is likely to grow slowly because of strict regulations and bad reimbursement policies.
